[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336478-105":59,"doc-detail-336478-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ercc3-gene-associated-with-breast-cancer-a-genetic-and-bioinformatic-study","ERCC3 Gene Associated with Breast Cancer - A Genetic and Bioinformatic Study","","Female breast cancer is the most common cancer in women and a major cause of cancer mortality worldwide, shaped by genetic, hormonal, and environmental influences. This research investigates ERCC3 as a breast cancer susceptibility gene by analyzing 291 patients and 291 controls from mainland China using genetic methods plus bioinformatic profiling and immunohistochemistry. A novel ERCC3 mutation p.Y116X is detected in a breast cancer family, with no significant genotype or allele frequency bias for rs754010782 and rs371627165. ERCC3 expression is negatively linked to ER/PR status, non-triple-negative features, and nodal status, while ERCC3 copy number alterations show distinct tumor-type patterns. The p.Y116X-associated lower ERCC3 expression is confirmed by IHC, supporting ERCC3 as a potential biomarker and risk factor in Han Chinese.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ercc3-gene-associated-with-breast-cancer-a-genetic-and-bioinformatic-study/336478/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ercc3-gene-associated-with-breast-cancer-a-genetic-and-bioinformatic-study/336478.png","ImageObject",300,407,{"name":92,"@type":93},"Noah","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study designed to investigate regarding ERCC3 and breast cancer?","Question",{"text":112,"@type":113},"The study explored the role of ERCC3 mutations in breast cancer development and pathological diagnosis by combining genetic analysis, bioinformatic analysis, and immunohistochemistry.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many participants were included and how were cases and controls selected?",{"text":117,"@type":113},"The study included 291 Han-Chinese female breast cancer patients and 291 cancer-free controls. Cases and controls were matched by age (±2 years) at a 1:1 ratio, with controls having no medical record of cancer.",{"name":119,"@type":110,"acceptedAnswer":120},"What key mutation and biomarker associations were reported for ERCC3?",{"text":121,"@type":113},"A novel ERCC3 mutation p.Y116X was identified, and ERCC3 expression was reported to be negatively associated with ER/PR status, non-triple-negative status, and nodal status. ERCC3 is proposed as a potential biomarker for pathological diagnosis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336478,1790824125,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","Wiley  \nThe Breast Journal  \nVolume 2024, Article ID 7278636, 12 pages [https://doi.org/10.1155/2024/7278636](https://doi.org/10.1155/2024/7278636)  \nResearch Article  \nERCC3 Gene Associated with Breast Cancer: A Genetic and Bioinformatic Study  \nXiangyu Chen , 1,2 Heng Xiao ,3 Shuangcheng Ning ,2 Bang Liu ,2 Huashan Zhou , 1,2 and Ting Fu 1,2  \n1 Department of Pathology, Changsha Hospital for Maternal and Child Health Care, Hunan Normal University,  \nChangsha, Hunan, China  \n2 Hunan Provincial Key Laboratory of Regional Hereditary Birth Defects Prevention and Control,  \nChangsha Hospital for Maternal and Child Care, Hunan Normal University, Changsha, Hunan, China  \n3 Department of Pathology, School of Medicine, Hunan Normal University, Changsha, Hunan, China  \nCorrespondence should be addressed to Huashan Zhou; zpathology@163.com and Ting Fu; [futing8826@163.com](futing8826@163.com)  \nReceived 7 February 2024; Accepted 27 June 2024  \nAcademic Editor: Pranshu Sahgal  \nCopyright © 2024 Xiangyu Chen et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nFemale breast cancer is the most common and the ffth deadliest cancer worldwide. It is infuenced by a combination of genetic, hormonal, and environmental factors. Te excision repair cross-complementation group 3 gene (ERCC3) has recently been identifed as a breast cancer susceptibility gene in various cohorts of diferent geographical and ethnic origin. To explore the role of ERCC3 mutations in breast cancer development and pathological diagnosis, genetic analysis was conducted in 291 patients and  \n291 controls from mainland China. Bioinformatic analysis and immunohistochemistry (IHC) were performed. A novel ERCC3 mutation p.Y116X was identifed in a breast cancer family, while no frequency bias for the genotype and allele ofrs754010782 andrs371627165 was observed (all P > 0.05) . Bioinformatic analysis revealed that ERCC3 expression was negatively associated with estrogen receptor (ER), progesterone receptor (PR), nontriple-negative status, and nodal status of breast cancers. ERCC3 amplifcations and deep deletions primarily occurred in breast invasive cancer not otherwise specifed (NOS) and metaplastic breast cancer, respectively. Te decreased ERCC3 expression in tumor tissues of patient with p.Y116X mutation was found by IHC. Te ERCC3 mutation p.Y116X may increase breast cancer risk in the Han-Chinese population. ERCC3 exhibits potential asa biomarker for the pathological diagnosis of breast cancer.  \n1. Introduction  \nFemale breast cancer is the most common and the ffth deadliest cancer, accounting for an estimation of 2.26 million newly diagnosed cases and 6.85 million new cancer-related deaths worldwide yearly [1]. It is a heterogeneous disease and its incidence is under the interactive efect of genetic, hormonal, and environmental factors [2]. Breast cancer diagnosed through histopathological analysis in female under the age of 40 years old are defned as early-onset breast cancer which is strongly linked to aggressive triple-negative or human epidermal growth factor 2 (HER2)-positive tumors [3]. Following a four-generation family with multiple female members afected frstly reported in 1866, a series of  \nepidemiological studies recognized genetic as an important risk∼factor for breast cancer, which explained approximately  \n5% 10% of the patients [4]. In recent decades, the advancement of candidate gene-association studies and genome-wide association studies (GWASs), along with meta-analysis of multiple GWAS, has greatly expedited the identifcation of susceptibility single nucleotide polymorphisms (SNPs), which have been estimated to contribute to approximately 41% of the heritability of breast cancer [5–7]. In addition, more than half of familial cases are ofundefned genetic cause [8]. Exploration of the geno","cbCaipVVjY1nguPl","https://ap.wps.com/l/cbCaipVVjY1nguPl","pdf",2770025,12,"English","# Introduction\n## Materials and Methods\n### Subjects and Pathological Diagnosis","[{\"question\":\"What was the study designed to investigate regarding ERCC3 and breast cancer?\",\"answer\":\"The study explored the role of ERCC3 mutations in breast cancer development and pathological diagnosis by combining genetic analysis, bioinformatic analysis, and immunohistochemistry.\"},{\"question\":\"How many participants were included and how were cases and controls selected?\",\"answer\":\"The study included 291 Han-Chinese female breast cancer patients and 291 cancer-free controls. Cases and controls were matched by age (±2 years) at a 1:1 ratio, with controls having no medical record of cancer.\"},{\"question\":\"What key mutation and biomarker associations were reported for ERCC3?\",\"answer\":\"A novel ERCC3 mutation p.Y116X was identified, and ERCC3 expression was reported to be negatively associated with ER/PR status, non-triple-negative status, and nodal status. ERCC3 is proposed as a potential biomarker for pathological diagnosis.\"}]","ERCC3 Gene Associated with Breast Cancer - A Genetic and Bioinformatic Study | PDF",1790015242,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c71306fc28f7a597ffe4a8fa4dc5e9e.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d7f5807033a0d5a5c024351aa07512b9.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/388134269c309313410c0ea3100aa79a.webp",981,1307,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/40ebb1ae6d380b389d59f81cd6fe12df.webp",980,1306]